Episode 3: How Company Healthcare Exchanges Could Affect The Industry
02/25/16 • 8 min
In this episode, healthcare analyst Arthur Wong shares his thoughts on the potential rise of company healthcare exchanges and what impact these entities may have on the pharmaceutical industry and pharmaceutical company ratings.
In this episode, healthcare analyst Arthur Wong shares his thoughts on the potential rise of company healthcare exchanges and what impact these entities may have on the pharmaceutical industry and pharmaceutical company ratings.
Next Episode
Episode 4: What's Behind The Ratings On Amgen
In this episode, healthcare analysts Arthur Wong and Adam Dibe address questions regarding the prospects for Amgen's core portfolio, its drug pipeline, the competition, and its increasing capacity for acquisitions.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/s-and-p-pharma-dose-101886/episode-3-how-company-healthcare-exchanges-could-affect-the-industry-5355264"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to episode 3: how company healthcare exchanges could affect the industry on goodpods" style="width: 225px" /> </a>
Copy